# Anupam Rasayan India share price today (Anupam Rasayan India Ltd, NSE: ANURAS) > Anupam Rasayan India share price today: ₹1,321.10 at the NSE close on 18 November 2026, up 6.0% in a year. Anupam Rasayan India (NSE: ANURAS) is worth ₹15,036 crore, trades at a P/E of 83.4 and has closed between ₹1,101.60 and ₹1,376.00 over the past 52 weeks. > Anupam Rasayan India Ltd's earnings have grown faster than its share price. Earnings per share grew +76.0% in a year while the price moved +6.0%. ANURAS · Speciality Chemicals · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Mixed, from fewer quarters than usual - Price: ₹1,321.10 (+6.0% in a year) - P/E: 83.4× (higher than 55% of the last 5.6 years) - Revenue (Sep 2026): ₹806 Cr (+10.3% on a year ago) - Profit (Sep 2026): ₹65.0 Cr (+14.0% on a year ago) - Operating margin: 23.2% (+4.6 points on a year ago) - ROCE: 7%, FY26 - Profit that came in as cash: 66%, last 3 years The main question: yearly earnings per share moved +76.0% while the share price moved +6.0%. ## What is the Anupam Rasayan India share price today? Anupam Rasayan India Ltd's share price was ₹1,321.10 at the close on 18 November 2026. It has been falling for 7 weeks. That is 9.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,102 and ₹1,376, and at that close it sat 80% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 5.6 years the share price moved +167% while the NIFTY 500 moved +95%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Anupam Rasayan India this quarter? 1. Revenue up on a year earlier for 8 quarters in a row In the September 2026 quarter revenue was ₹806 crore, +10.3% on a year earlier. Why: Revenue rose because the company sold more performance materials and had a better mix of products. Next results: check whether second half revenue shows the full contribution from all four businesses. From the earnings call on 6 Nov 2026. 2. Highest quarterly profit in 14 quarters Profit of ₹65 crore in the September 2026 quarter is the highest of the last 14 quarters. Why: Profit rose because the company had a bigger share of performance materials and a better product mix. Next results: check whether the stronger profit margin lasts, since management kept its margin aim unchanged and expects more pharma and performance materials in the mix. From the earnings call on 6 Nov 2026. 3. The 200-day average is the share's average price over about ten months. It closed at ₹1300.6 on 13 Nov 2026, above that average of ₹1211. ## What are Anupam Rasayan India's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Anupam Rasayan India reported revenue of ₹806 crore, up 10.3% from ₹731 crore a year earlier, and a profit of ₹65.0 crore, up 14.0% from ₹57.0 crore. ### Anupam Rasayan India results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹806 crore | ₹731 crore | +10.3% | | Profit | ₹65.0 crore | ₹57.0 crore | +14.0% | | Earnings per share | ₹4.39 | ₹3.90 | +12.6% | | Operating margin | 23.2% | 18.6% | +4.6 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Anupam Rasayan India's management discussed these results on a call held on 6 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Anupam Rasayan India share price history? Anupam Rasayan India closed at ₹1,321.10 on 18 November 2026, up 6.0% from ₹1,246.80 a year earlier (21 November 2025) and up 62.1% over five years. Its highest weekly close since March 2021 was ₹1,376.00 on 15 May 2026. ### Anupam Rasayan India share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,191.90 | +10.8% | | 1 month ago · 19 Oct 2026 | ₹1,109.70 | +19.1% | | 6 months ago · 15 May 2026 | ₹1,376.00 | −4.0% | | 1 year ago · 21 Nov 2025 | ₹1,246.80 | +6.0% | | 3 years ago · 17 Nov 2023 | ₹931.60 | +41.8% | | 5 years ago · 18 Nov 2021 | ₹815.05 | +62.1% | | Earliest and lowest weekly close in our records · 26 Mar 2021 | ₹495.70 | +166.5% | | Highest weekly close since March 2021, also the 52-week high · 15 May 2026 | ₹1,376.00 | −4.0% | | 52-week low (weekly close) · 23 Oct 2026 | ₹1,101.60 | +19.9% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (303 weekly closes from 26 March 2021 to 18 November 2026.) ## What is the latest news on Anupam Rasayan India? 18 Nov 2026: Anupam Rasayan India closed at ₹1,321.10, up 10.8% on the week and up 19.1% on the month. 6 Nov 2026: Anupam Rasayan India held its results call for July to September 2026. Management guided: H2FY27 consolidated revenue around ₹2,400-2,500 crore implying ₹4,800-5,000 crore annualized run-rate. ### Earlier - Results for July to September 2026: Revenue up 10.3% and profit up 14.0% on a year earlier. - 18 Sep 2026: ex-date for a dividend of ₹1.50 a share. ## What dividend does Anupam Rasayan India pay? Anupam Rasayan India paid ₹1.50 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.11% at the ₹1,321.10 close on 18 November 2026. The last was a dividend of ₹1.50 a share, ex-date 18 September 2026. ### Anupam Rasayan India dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 18 Sep 2026 | ₹1.50 | Dividend | same day | | 21 Jul 2025 | ₹0.75 | Interim | same day | | 17 Sep 2024 | ₹0.75 | Dividend | 18 Sep 2024 | | 20 Nov 2023 | ₹0.50 | Interim | same day | | 15 May 2023 | ₹1.50 | Interim | same day | | 8 Feb 2023 | ₹0.60 | Interim | same day | | 2 Sep 2022 | ₹1 | Dividend | 5 Sep 2022 | | 3 Aug 2022 | ₹0.40 | Interim | 4 Aug 2022 | | 17 Nov 2021 | ₹0.50 | Interim | 18 Nov 2021 | | 15 Sep 2021 | ₹0.50 | Dividend | 16 Sep 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Anupam Rasayan India Ltd paid out 10% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 12 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Anupam Rasayan India management say on the latest results call? On the call for July to September 2026, held on 6 November 2026, Anupam Rasayan India's management guided: H2FY27 consolidated revenue around ₹2,400-2,500 crore implying ₹4,800-5,000 crore annualized run-rate. > “As the overall contribution from pharmaceuticals and performance materials increases and becomes a larger share of the group's revenue mix, we expect revenue cyclicality to reduce over the next 4-8 quarters.” > Amit Khurana, on the call for July to September 2026 ### What management guided - Organic revenue growth 20-25% over near-term 3-5 year period planned. - United States metal pact balance ₹100-150 crore this year with monthly run-rate doubling over next 12-18 months. - Bliss steady-state operating margin 22-24% aligned to consolidated average goal. - Long-term agreement revenue this year 1.8-2.0 times prior base of around ₹350 crore. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/42195/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 6 November 2026.) ## What to watch in Anupam Rasayan India's next results? When Anupam Rasayan India reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Consolidated second-half revenue on full four-entity contribution scale-up - check print against flagged stronger-half goal. Management raised each of these on the latest results call. - Consolidated second-half revenue on full four-entity contribution scale-up - check print against flagged stronger-half goal. - United States metal supply ramp from imminent start - check monthly volumes against flagged balance and doubling path. - Bliss first full-quarter contribution with utilization lift - check operating print against flagged synergy window and margin framework. ## Which stock lists is Anupam Rasayan India on? Anupam Rasayan India is on 2 of our India lists: Momentum stocks and Small & mid cap stocks. - [Momentum stocks Market value: ₹14,999 crore](https://www.sectoralpha.in/momentum-stocks-india) - [Small & mid cap stocks Size rank in India: 467](https://www.sectoralpha.in/small-cap-stocks-india) ## Is Anupam Rasayan India profitable? Anupam Rasayan India Ltd earned ₹65.0 Cr of net profit in the Sep 2026 quarter, +14.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹222 Cr. Over 10 years profit has grown 20.0% a year on average. The same quarter a year earlier earned ₹57.0 Cr. The Sep 2026 quarter's profit is 8.1% of that quarter's revenue. For the full year, FY26 profit was ₹222 Cr (+38.7% on the year before). Why profit moved: revenue changed +10.3% on a year earlier and the margin moved +4.6 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +5.5% and revenue +25.9%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Anupam Rasayan India make, and is it growing? Anupam Rasayan India Ltd reported ₹806 Cr of revenue in the Sep 2026 quarter, +10.3% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 24.1% a year on average. The last full year, FY26, came in at ₹2,365 Cr. Why this happened. Jayhawk provides what Anupam previously lacked: direct US onshore manufacturing validated with American customers. This addresses the critical barrier for large multinational customers who demand 'strong, credible full supply chain solutions, not import-and-process models.' Jayhawk brings established customer relationships in semiconductor, aerospace, pharma, and EV/automotive end-markets. The strategic logic is strong: most competitors cannot offer an integrated India→US fluorine supply chain. The caution: EPS accretion claim is management assertion, unverified until Q4 FY26 actuals. The last four reported quarters add to ₹2,609 Cr. FY26 revenue was ₹2,365 Cr, +64.6% on the year before. Recent pace: the last four quarters grew +25.9% on average, against 24.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +23.8%, against +44.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +5.0%, against +46.2% a year (rolling over). ## How much of every ₹100 of sales does Anupam Rasayan India keep? Anupam Rasayan India Ltd's operating margin was 23.2% in the Sep 2026 quarter, 4.6 percentage points higher than the same quarter a year ago. Across 12 years it has been between 18.5% and 28.4%. The latest quarter is within that range. Why this happened. The pharma strategy goals the KSM (Key Starting Material) space where Indian players have not yet built manufacturing depth. Anupam launched 9 molecules in FY25 (5 pharma) and 17 new molecules over 18 months, these are now ramping to revenue. High-value molecules across CNS, statins, and infectious disease create long-term supply agreements (3-5 year customer validation cycles). The 85% YoY growth is multi-quarter and structural, not a one-off. Why the margin moved: operating margin changed +4.7 percentage points on the year while gross margin changed +14.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Anupam Rasayan India's profit turning into cash? Over the last 3 years, 66% of Anupam Rasayan India Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹334 Cr of operating cash against ₹222 Cr of profit. After ₹555 Cr of spending on assets, free cash was −₹221 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 66% of profit came in as cash: the cash cycle got 31 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: the bigger use of cash is spending on new assets, at 5.2× depreciation over three years. The next section checks what that spending is building. ## Where does Anupam Rasayan India's cash go? Anupam Rasayan India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 377 days in FY26, down from 408 days in FY21. It spent ₹1,681 Cr on assets over the last 3 years. Customers take 148 days to pay, and stock sits for 490 days on average. At FY26 sales of ₹2,365 Cr, each day of that cycle ties up about ₹6.5 Cr, so roughly ₹2,443 Cr is tied up in the business at any time. FY26: customers took 148 days to pay and stock sat for 490 days, about 16.1 months of sales sitting as stock, for a full cycle of 377 days, shorter than FY21's 408. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 490 days. Customers pay about 148 days after that. Suppliers are paid at 261 days. Together that makes the 377-day cycle. Spending on assets: ₹1,681 Cr over the last 3 years, against ₹322 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹114 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Anupam Rasayan India's P/E ratio, and how does it compare with its own history? Anupam Rasayan India Ltd's P/E is 83.4×, in the middle of its own history: higher than 55% of past readings. Its usual P/E (the middle reading) is 80.8×, over 5.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +76.0% while the price moved +6.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +10.1% a year; about +7.2% a year came from earnings growth and about +2.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 63% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Anupam Rasayan India business getting better or worse? Anupam Rasayan India Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: revenue growth has eased from +66.5% at its peak to +23.8%, but the business is still expanding, with ROCE falling at 7.0% (four quarters to FY26). This is based on 10 quarters of 4 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is the Anupam Rasayan India story, and has it been checked? Anupam Rasayan India Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: recovery mid. Our read, 17 May 2026. A fluorine chemistry platform in mid-transition, revenue inflecting hard but capital returns still depressed, with a US acquisition that could either unlock the next leg or drag integration costs. From the numbers. EPS… From the price. Price stage 4, week 7, above its 200-day line, relative strength rising. Where they disagree. EPS recovery is real (PAT +71% YoY in 9M FY26) but ROCE and ROE remain depressed at 7.33% and 3.32% respectively. DII stake-cutting adds a cautionary institutional signal. What is not proven yet. Management has now missed the WC goal twice (FY26 goal pushed to FY27). At 250 days, Rs 730 Cr net debt, and Rs 35-36 Cr/quarter interest, FCF remains deeply negative and growth requires dilution or further debt. The test written in advance. Working Capital at 250 days, Cash Flow Drag Persists. Measured by: Working Capital at 250 days, Cash Flow Drag Persists Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal) by the next result. The test written in advance. PAT Margin Dilution from New Molecule Ramp. Measured by: PAT Margin Dilution from New Molecule Ramp Q4 FY26 and Q1 FY27 OPM trajectory, must recover toward 27-28% as mix shifts to higher-margin molecules by the next result. The test written in advance. Jayhawk Integration Risk. Measured by: Jayhawk Integration Risk Q4 FY26 concall: confirmation of closing date, Jayhawk revenue contribution, and integration timeline by the next result. What the company does. 9M FY26 revenue Rs 1,730 Cr (+84% YoY) after FY25 contraction; Pharma +85% and Performance Materials +245% driving the recovery, with the agro segment also bouncing back. Jayhawk (US specialty chemicals) acquisition closing FY26-end creates a full-stack fluorine supply chain India→US; EPS accretive from day one per management, unverified until Q4 FY26 actuals land. Lever 2 · Value-added mix: building. Pharma revenue +85% YoY in 9M FY26; 30+ molecules in R&D/pilot including Apixaban, Statins, Sitagliptin, Venetoclax. Input substitution for KSMs not yet addressed by Indian players. What proves it keeps working: Pharma Segment Ramp (KSM / API input substitution). It stops working if Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal). Lever 3 · Management change: building. Performance Materials +245% YoY in 9M FY26 (17% of revenue); 35+ molecules in development for semiconductors, aerospace, EV, automotive. Dual LiPF6 LOIs with E-Lyte Innovations (EU) and Elementium (US) signed. What proves it keeps working: Performance Materials, Defense, Electronics, EV Chemistry. Lever 10 · New geographies: building. 100% acquisition of US-based Jayhawk Fine Chemicals closing within weeks of Feb 2026 call. Creates Tanfac→Anupam→Jayhawk full fluorine supply chain. EPS accretive day one per management. What proves it keeps working: Jayhawk Acquisition, US Onshore Manufacturing. Lever 6 · Order-book wins: building. Rs 14,646 Cr order book (4-10 year spread); Rs 3,100 Cr already commercialized (>20% of FY25 revenue); Rs 250+ Cr from LOIs and contracts converted in 9M FY26. What proves it keeps working: Order Book Conversion, Rs 14,646 Cr LOI Pipeline. Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Anupam Rasayan India management deliver what it promised? What Anupam Rasayan India Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Jayhawk Consolidation Period Does Not Reconcile · 6 November 2026. The May 2026 call said Jayhawk had contributed only 1 month and 2 days in FY26 and that its full contribution would be visible in FY27; the Aug 2026 call characterized FY27 as the first full year of consolidation. Yet the Nov 2026 Q2 and H1 FY27 call still described Jayhawk as consolidated for only 4 months, which does not reconcile with the intervening Q1 and Q2 and could materially distort consolidated revenue and run-rate assumptions. Working Capital Is Above Prior Pro Forma Range · 6 November 2026. The May 2026 call described consolidated working capital of 215-220 days on a pro forma basis and 240-250 days excluding Jayhawk, while the Nov 2026 call reported 271 days even after excluding the Bliss balance sheet. Management explained the Bliss consolidation timing, but that does not reconcile the ex-Bliss figure with the earlier working-capital outlook, creating a material cash-conversion issue for modeling. Bliss Leadership Continuity Has Changed Without Explanation · 6 November 2026. The May 2026 call explicitly promised that Bliss's current management would continue, while the Aug 2026 call emphasized retaining the acquired businesses' independence and existing management. The Nov 2026 call simultaneously said the team remained the same and disclosed a newly appointed CEO, without explaining whether this supersedes or supplements the prior continuity commitment. EBITDA Margin Guidance Downgrade · 25 May 2026. In the Oct 2025 call, management confidently projected structural EBITDA margins to stabilize around 25% going forward. However, in the May 2026 call, they quietly walked back this guidance, resetting future expectations to align with "this year's numbers" (FY26 reported EBITDA margin was 23%) without explaining the 200 basis point downgrade. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Anupam Rasayan India earn on its capital? Anupam Rasayan India Ltd earned a ROCE of 7% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 9.4% net margin and 0.30× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 9.4% net margin × 0.30× asset turnover × 2.43× leverage (assets divided by equity) ≈ 6.9% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 63% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Anupam Rasayan India have too much debt? Anupam Rasayan India Ltd had ₹1,867 Cr of borrowings against ₹3,302 Cr of equity in FY26, so its debt is 0.57× its equity. Its operating profit is 4 times its interest bill. Over 5 years borrowings went from ₹423 Cr to ₹1,867 Cr. Over the last 3 of those years it spent ₹1,681 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 63% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Anupam Rasayan India shareholding pattern? Promoters cut their stake in Anupam Rasayan India Ltd by 2.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 59.1% of the company. Foreign institutions moved +1.7 points over the same period, to 8.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. The performance materials segment is Anupam's highest-optionality exposure. 245% YoY growth in 9M FY26 reflects commercialization of contracts signed in FY25, including a Japan multinational MPA for semiconductor-grade molecules and E-Lyte Innovations LOI for electrolyte solutions. The structural tailwind is EV supply chain diversification away from China and data center buildout requiring specialty electronic chemicals. Long customer qualification cycles (3-5 years) mean once validated, the revenue base is sticky. Over the last two years: Promoters: −2.2 points over 8 quarters, to 59.1%; Foreign institutions: +1.7 points over 8 quarters, to 8.7%; Domestic institutions: +0.0 points over 8 quarters, to 2.3%. Why the owners changed: promoters drove it (−2.2 points), with the other side taken by foreign institutions (+1.7 points). They reduced their stake. ## How far is Anupam Rasayan India from balance-sheet trouble? For Anupam Rasayan India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Anupam Rasayan India rank in its industry? 48.9 out of 100, rank 18 of 30 in Speciality Chemicals, with 82% of the evidence available. Anupam Rasayan India Ltd scores 48.9 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 18. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.3 + 11.1 + 8.6 + 9.9 = 48.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Anupam Rasayan India compared with? Anupam Rasayan India ranks 18 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 48.9 out of 100. 1. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) PANAMAPET · losing its lead · Most evidence points up · 90% evidence 77.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 33.5/35 · Revenue 75% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 17.2/25 · ROCE 19.2% (year to Mar 2026) · Operating margin 17.2% · 100% evidence Valuation 14.6/20 · P/E 3.8× · PEG n/a · 50% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 12.1% · Strength vs NIFTY 500 (same reading) 15.8% · 1 year 39.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 33.5 + 17.2 + 14.6 + 11.9 = 77.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) GALAXYSURF · losing its lead · Most evidence points up · 85% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 30.2% · Profit 42.3% · Operating margin change 2 points · 100% evidence Capital efficiency 11.9/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 10.5% · 100% evidence Valuation 16.2/20 · P/E 19.3× · PEG 1.14 · 100% evidence Relative strength 11.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 6.9% · 1 year 7.5% · 25% evidence · 11 of 12 weeks ahead Exact sum: 28 + 11.9 + 16.2 + 11.3 = 67.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) BLACKROSE · quiet · Most evidence points up · 75% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 13% · Profit 65% · Operating margin change 5 points · 100% evidence Capital efficiency 14.8/25 · ROCE 18.7% (year to Mar 2026) · Operating margin 13.6% · 100% evidence Valuation 14.4/20 · P/E 15.3× · PEG n/a · 50% evidence Relative strength 9.8/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 0.6% · 1 year n/a · 25% evidence · 6 of 12 weeks ahead Exact sum: 27.4 + 14.8 + 14.4 + 9.8 = 66.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) YASHO · losing its lead · Evidence leans up · 68% evidence 64.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidence Capital efficiency 12.6/25 · ROCE 8.9% (year to Mar 2026) · Operating margin 21% · 100% evidence Valuation 9.1/20 · P/E 52.1× · PEG n/a · 15% evidence Relative strength 12.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 44% · 1 year 126.5% · 25% evidence · 9 of 12 weeks ahead Exact sum: 30.4 + 12.6 + 9.1 + 12.2 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) FCL · leader · Evidence leans up · 100% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 100% · Profit 68.7% · Operating margin change -8 points · 100% evidence Capital efficiency 13.8/25 · ROCE 18.3% (year to Mar 2026) · Operating margin 15.5% · 100% evidence Valuation 9.1/20 · P/E 39.9× · PEG 1.13 · 100% evidence Relative strength 18.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 42.8% · Strength vs NIFTY 500 (same reading) 45.9% · 1 year 81.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.8 + 13.8 + 9.1 + 18.2 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) TATVA · losing its lead · Evidence leans up · 93% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.9/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidence Capital efficiency 8.8/25 · ROCE 7.2% (year to Mar 2026) · Operating margin 18.9% · 100% evidence Valuation 10.3/20 · P/E 61.3× · PEG 1.23 · 65% evidence Relative strength 13.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.4% · Strength vs NIFTY 500 (same reading) 15.7% · 1 year 13.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 28.9 + 8.8 + 10.3 + 13.1 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) PRIVISCL · quiet · Evidence leans up · 82% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidence Capital efficiency 18.6/25 · ROCE 22.3% (year to Mar 2026) · Operating margin 26.3% · 76% evidence Valuation 9.8/20 · P/E 36× · PEG n/a · 50% evidence Relative strength 8.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.5% · Strength vs NIFTY 500 (same reading) 0.9% · 1 year 9.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.6 + 18.6 + 9.8 + 8 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) breaking out · Evidence leans up · 72% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change -4 points · 95% evidence Capital efficiency 21.2/25 · ROCE 36.2% (year to Mar 2026) · Operating margin 40.9% · 95% evidence Valuation 7.4/20 · P/E 21.7× · PEG n/a · 50% evidence Relative strength 12.0/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 39.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 18.8 + 21.2 + 7.4 + 12 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) AARTIIND · losing its lead · Evidence leans up · 100% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 39.8% · Profit 100% · Operating margin change -3 points · 100% evidence Capital efficiency 9.8/25 · ROCE 6.9% (year to Mar 2026) · Operating margin 11.2% · 100% evidence Valuation 13.7/20 · P/E 28.3× · PEG 0.93 · 100% evidence Relative strength 9.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -0.6% · Strength vs NIFTY 500 (same reading) 4% · 1 year 20.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.4 + 9.8 + 13.7 + 9.1 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) CHEMCON · breaking out · Evidence leans up · 75% evidence 55.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 22.3% · Profit 20.2% · Operating margin change 4.1 points · 100% evidence Capital efficiency 8.8/25 · ROCE 6.3% (year to Mar 2026) · Operating margin 16.9% · 100% evidence Valuation 11.3/20 · P/E 23.4× · PEG n/a · 50% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 5.1% · 1 year -12.6% · 25% evidence · 9 of 12 weeks ahead Exact sum: 24.1 + 8.8 + 11.3 + 11.2 = 55.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) AETHER · losing its lead · Evidence leans up · 100% evidence 53.8 out of 100 Growth Capital Valuation Relative 12. [Kronox Lab Sciences Ltd](https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd) KRONOX · breaking out · Evidence leans up · 68% evidence 53.6 out of 100 Growth Capital Valuation Relative 13. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) PAUSHAKLTD · losing its lead · Evidence leans up · 75% evidence 51.5 out of 100 Growth Capital Valuation Relative 14. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ALKYLAMINE · quiet · Evidence leans up · 100% evidence 51.0 out of 100 Growth Capital Valuation Relative 15. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) NEOGEN · leader · Evidence leans up · 100% evidence 50.8 out of 100 Growth Capital Valuation Relative 16. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) PLATIND · turning · Evidence leans down · 75% evidence 49.9 out of 100 Growth Capital Valuation Relative 17. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) PIDILITIND · quiet · Evidence leans down · 100% evidence 49.3 out of 100 Growth Capital Valuation Relative 18. Anupam Rasayan India Ltd this page ANURAS · turning · Evidence leans down · 82% evidence 48.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 23.8% · Profit 5% · Operating margin change 4 points · 95% evidence Capital efficiency 11.1/25 · ROCE 7.4% (year to Mar 2026) · Operating margin 23.2% · 76% evidence Valuation 8.6/20 · P/E 83.4× · PEG n/a · 50% evidence Relative strength 9.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.5% · Strength vs NIFTY 500 (same reading) -0.5% · 1 year 6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 19.3 + 11.1 + 8.6 + 9.9 = 48.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 19. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) SUNSHIEL · quiet · Evidence leans down · 75% evidence 48.2 out of 100 Growth Capital Valuation Relative 20. [Grauer & Weil (India) Ltd](https://www.sectoralpha.in/stocks/grauer-weil-indialtd) GRAUWEIL · breaking out · Evidence leans down · 90% evidence 46.1 out of 100 Growth Capital Valuation Relative 21. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) AMNPLST · quiet · Evidence leans down · 75% evidence 45.7 out of 100 Growth Capital Valuation Relative 22. [DIC India Ltd](https://www.sectoralpha.in/stocks/dic-india-ltd) DICIND · Evidence leans down · 70% evidence 45.3 out of 100 Growth Capital Valuation Relative 23. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) DMCC · quiet · Evidence leans down · 83% evidence 43.4 out of 100 Growth Capital Valuation Relative 24. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) CLEAN · quiet · Evidence leans down · 85% evidence 43.1 out of 100 Growth Capital Valuation Relative 25. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) VINATIORGA · quiet · Evidence leans down · 82% evidence 43.1 out of 100 Growth Capital Valuation Relative 26. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) AMAL · quiet · Evidence leans down · 68% evidence 43.1 out of 100 Growth Capital Valuation Relative 27. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) breaking out · Too little evidence to rank firmly · 57% evidence 40.3 out of 100 Growth Capital Valuation Relative 28. [Transpek Industry Ltd](https://www.sectoralpha.in/stocks/transpek-industry-ltd) TRANSPEK · turning · Evidence leans down · 67% evidence 38.6 out of 100 Growth Capital Valuation Relative 29. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) VISHNU · losing its lead · Evidence leans down · 90% evidence 37.6 out of 100 Growth Capital Valuation Relative 30. [Thirumalai Chemicals Ltd](https://www.sectoralpha.in/stocks/thirumalai-chemicals-ltd) TIRUMALCHM · quiet · Most evidence points down · 71% evidence 34.0 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Speciality Chemicals](https://www.sectoralpha.in/sectors/speciality-chemicals), all 30 compared on one page. ## Which companies are close to Anupam Rasayan India in size? Anupam Rasayan India is the 4th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Pidilite Industries, Aether Industries and Aarti Industries. Just below it: Privi Speciality Chemicals, Vinati Organics and Neogen Chemicals. ### Speciality Chemicals companies close in size 1. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) ₹1,55,857 crore 2. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) ₹21,865 crore 3. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) ₹16,778 crore 4. Anupam Rasayan India Ltd ₹15,040 crore 5. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) ₹13,431 crore 6. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) ₹11,906 crore 7. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) ₹8,352 crore [All 30 Speciality Chemicals companies, largest first](https://www.sectoralpha.in/sectors/speciality-chemicals#all-companies) ### Companies close in size in other industries 1. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) ₹15,064 crore · Pesticides/Agrochemicals 2. [Swan Defence and Heavy Industries Ltd](https://www.sectoralpha.in/stocks/swan-defence-and-heavy-industries-ltd) ₹15,047 crore · Ship - Docks/Breaking/Repairs 3. Anupam Rasayan India Ltd ₹15,040 crore 4. [Clean Max Enviro Energy Solutions Ltd](https://www.sectoralpha.in/stocks/clean-max-enviro-energy-solutions-ltd) ₹14,977 crore · Power Generation & Supply 5. [Azad Engineering Ltd](https://www.sectoralpha.in/stocks/azad-engineering-ltd) ₹14,976 crore · Aerospace & Defence - Equipments ## What else do people ask about Anupam Rasayan India? ### What is Anupam Rasayan India's share price today? Anupam Rasayan India Ltd's share price is ₹1,321.10, +6.0% over the past year. The whole company is worth ₹15,036 Cr on the market. In the last 52 weeks it traded between ₹1,102 to ₹1,376; today it is 80% of the way up from the low, 9.1% above its 200-day average (as of 18 November 2026). ### What were Anupam Rasayan India's latest quarterly results? Anupam Rasayan India Ltd reported revenue of ₹806 Cr and net profit of ₹65.0 Cr for the Sep 2026 quarter. Revenue rose 10.3% and profit rose 14.0% compared with a year earlier. Earnings per share were ₹4.39. The operating margin was 23.2%, 4.6 percentage points higher than a year earlier (as of 18 November 2026). ### What is Anupam Rasayan India's market cap? Anupam Rasayan India Ltd's market capitalisation is ₹15,036 Cr at a share price of ₹1,321.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Anupam Rasayan India performing? Anupam Rasayan India Ltd's share price has been falling for 7 weeks. In its latest quarter, revenue rose 10.3% and profit rose 14.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 18 November 2026). ### Will Anupam Rasayan India's share price go up? This page does not forecast Anupam Rasayan India Ltd's share price. What it shows instead: the share price is ₹1,321.10, and it has been falling for 7 weeks. Its P/E of 83.4× is higher than 55% of its own last 6 years (as of 18 November 2026). ### Who owns Anupam Rasayan India? Promoters own 59.1% of Anupam Rasayan India Ltd, foreign institutions 8.7%, domestic institutions 2.3% and the public 30.0% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 2.2 percentage points over 8 quarters (as of 18 November 2026). ### Where is Anupam Rasayan India in its business cycle? Anupam Rasayan India Ltd's FY26 operating margin was 22.2%, against a 12-year range of 18.5% to 28.4%. The latest quarter was 23.2%, the middle of its own range, neither a peak nor a low. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Anupam Rasayan India story? The main question: yearly earnings per share moved +76.0% while the share price moved +6.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Anupam Rasayan India a stock worth studying right now? What the numbers show: Anupam Rasayan India Ltd's earnings have grown faster than its share price. Earnings per share grew +76.0% in a year while the price moved +6.0%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Anupam Rasayan India share price forecast for 2026? What management itself guided: H2FY27 consolidated revenue around ₹2,400-2,500 crore implying ₹4,800-5,000 crore annualized run-rate. ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india This is research, not advice. We’re not SEBI-registered.